- Title: Subtitle
- Long-term patterns of safety and efficacy of bleeding prophylaxis with turoctocog alfa (NovoEight®) in previously treated patients with severe haemophilia A: interim results of the guardian™2 extension trial
- Creators
- M Ozelo - IHTC 'Claudio L.P. Correa', INCT do Sangue Hemocentro UNICAMP, University of Campinas, Sao Paulo, BrazilM Misgav - National Hemophilia Center, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, IsraelF Abdul Karim - National Blood Centre, Kuala Lumpur, MalaysiaS. R Lentz - The University of Iowa Carver College of Medicine, IA, Iowa City, USAM Martin-Salces - Haematology Department, Hospital Universitario La Paz, Madrid, SpainI Matytsina - Novo Nordisk A/S, Soeborg, DenmarkT Saugstrup - Novo Nordisk A/S, Soeborg, DenmarkE Santagostino - Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Maggiore Hospital Policlinico, Milan, Italy
- Resource Type
- Letter/Communication
- Publication Details
- Haemophilia : the official journal of the World Federation of Hemophilia, Vol.21(5), pp.e436-e439
- DOI
- 10.1111/hae.12737
- PMID
- 26058730
- NLM abbreviation
- Haemophilia
- ISSN
- 1351-8216
- eISSN
- 1365-2516
- Publisher
- Blackwell Publishing Ltd
- Number of pages
- 4
- Grant note
- name: Novo Nordisk A/S
- Language
- English
- Date published
- 09/2015
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984094576202771
Letter/Communication
Long-term patterns of safety and efficacy of bleeding prophylaxis with turoctocog alfa (NovoEight®) in previously treated patients with severe haemophilia A: interim results of the guardian™2 extension trial
Haemophilia : the official journal of the World Federation of Hemophilia, Vol.21(5), pp.e436-e439
09/2015
DOI: 10.1111/hae.12737
PMID: 26058730
Details
Metrics
24 Record Views